Associated tags: EUR, Parallel, EBITDA
Locations: , GERMANY, BELGIUM, SPAIN, AUSTRIA, UNITED STATES, EUROPE, ITALY, SWITZERLAND, NETHERLANDS, FRANCE, PORTUGAL
Retrieved on:
Saturday, December 30, 2023
Consolidated revenue and EBITDA (adjusted) stay on course, climbing to EUR 866.6 million and EUR 243.8 million, respectively
Key Points:
- Consolidated revenue and EBITDA (adjusted) stay on course, climbing to EUR 866.6 million and EUR 243.8 million, respectively
Grünwald, 15 November 2023 – Dermapharm Holding SE ("Dermapharm"), an innovative rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its results for the first nine months of 2023.
- The Group increased revenue by 18.0% to EUR 866.6 million in the reporting period (prior-year period: EUR 734.3 million).
- 9M 2023 adjusted EBITDA amounts to EUR 183.8 million (prior-year period: EUR 216.9 million).
- Accordingly, adjusted EBITDA also saw a pronounced increase of 154.2% to EUR 63.3 million (prior-year period: EUR 24.9 million).
Retrieved on:
Wednesday, December 13, 2023
Rabatt,
Prognose,
Abschreibung,
Dermapharm,
Krankenkasse,
Zins,
Bereich,
Holding,
Monat,
EBITDA,
Produkt-Markt-Matrix,
Sicherheit,
Auslaufen,
Basis,
Steuer,
Mitarbeiter,
Vorstand,
Million,
Gesetz,
Segment,
SE,
Produktion,
Konzern,
Produkt,
Entwicklung,
Nachfrage,
Quartal,
Prozentzeichen,
Steigerung,
Umsatz,
Mio,
Ergebnis,
Zug,
Umsetzung,
Sale,
DR,
Werbung
Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall
Key Points:
- Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall
The issuer is solely responsible for the content of this announcement.
- Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall
Consolidated revenue and EBITDA (adjusted) stay on course, climbing year on year to EUR 582.1 million and EUR 168.0 million, respectively
Grünwald, 29 August 2023 – Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its report for the first half of 2023 and confirmed the preliminary consolidated figures (IFRS).
- According to the finalised and reviewed IFRS consolidated figures, Dermapharm lifted its revenue in H1 2023 by 23.6% to EUR 582.1 million (previous year: EUR 471.1 million).
- H1 2023 adjusted EBITDA amounts to EUR 127.3 million (previous year: EUR 134.6 million).
BioNTech,
Tax,
Inflammation,
Marketing,
Pain,
EUR,
Dermatology,
EBITDA,
Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science,
Parallel,
Depreciation,
Growth,
Pharmaceutical industry Dermapharm successfully maintains its growth trend as planned in the first six months of financial year 2023.
Key Points:
- Dermapharm successfully maintains its growth trend as planned in the first six months of financial year 2023.
- "Despite a challenging market environment, our business has performed very successfully from an operational standpoint in the first half of 2023.
- The positive performance in the first half of 2023 laid a good foundation for the further course of the business.
- Dermapharm will publish its final figures for the first half of 2023 along with its complete 2023 half-yearly financial report on 29 August 2023.
Dronabinol,
Botanischer Garten für Arznei- und Gewürzpflanzen Oberholz,
Annual,
Supervisory board,
Mass meeting,
Aggression,
Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science,
EUR,
EBITDA,
Institut für Integrierte Produktion Hannover,
Acquisition,
Pharma,
Entwicklung und Erprobung von Leichtflugzeugen,
Annual general meeting,
Rope,
Management Grünwald, 14 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2023 Annual General Meeting.
Key Points:
- Grünwald, 14 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2023 Annual General Meeting.
- 22.53% of the share capital was in attendance at the Annual General Meeting, which was held in person.
- At the recommendation of the Board of Management, the Annual General Meeting resolved to distribute a dividend of EUR 1.05 per share.
- The total distribution amounts to EUR 56.5 million, representing a distribution ratio of approximately 42%.
Suppository,
Powder,
Table,
Marketing,
Tablet,
Dronabinol,
Parallel,
Made in Europe,
Urology,
Fine chemical,
Pharmaceutical industry,
Brehna Grünwald, 13 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, contractually acquired a significant interest in Pharmazeutische Fabrik Montavit Gesellschaft m.b.H.
Key Points:
- Grünwald, 13 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, contractually acquired a significant interest in Pharmazeutische Fabrik Montavit Gesellschaft m.b.H.
- ("Montavit"), Absam, Tyrol, Austria, via its wholly owned subsidiary Dermapharm AG on 7 June 2023.
- Montavit is a family-owned company founded in 1945 that develops and produces pharmaceuticals and medical devices.
- Montavit specialises in the urology, gynaecology, allergy therapy and herbal pharmaceuticals therapeutic areas and the manufacture of sterile catheter gels.